Cargando…
Regulator combinations identify systemic sclerosis patients with more severe disease
Systemic sclerosis (SSc) is a heterogeneous autoimmune disorder that results in skin fibrosis, autoantibody production, and internal organ dysfunction. We previously identified 4 “intrinsic” subsets of SSc based upon skin gene expression that are found across organ systems. Gene expression regulator...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Clinical Investigation
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7526449/ https://www.ncbi.nlm.nih.gov/pubmed/32721949 http://dx.doi.org/10.1172/jci.insight.137567 |
_version_ | 1783588877009682432 |
---|---|
author | Wang, Yue Franks, Jennifer M. Yang, Monica Toledo, Diana M. Wood, Tammara A. Hinchcliff, Monique Whitfield, Michael L. |
author_facet | Wang, Yue Franks, Jennifer M. Yang, Monica Toledo, Diana M. Wood, Tammara A. Hinchcliff, Monique Whitfield, Michael L. |
author_sort | Wang, Yue |
collection | PubMed |
description | Systemic sclerosis (SSc) is a heterogeneous autoimmune disorder that results in skin fibrosis, autoantibody production, and internal organ dysfunction. We previously identified 4 “intrinsic” subsets of SSc based upon skin gene expression that are found across organ systems. Gene expression regulators that underlie the SSc-intrinsic subsets, or are associated with clinical covariates, have not been systematically characterized. Here, we present a computational framework to calculate the activity scores of gene expression regulators and identify their associations with SSc clinical outcomes. We found that regulator activity scores can reproduce the intrinsic molecular subsets, with distinct sets of regulators identified for inflammatory, fibroproliferative, limited, and normal-like samples. Regulators most highly correlated with modified Rodnan skin score (MRSS) also varied by intrinsic subset. We identified subgroups of patients with fibroproliferative and inflammatory SSc with more severe pathophenotypes, such as higher MRSS and increased likelihood of interstitial lung disease (ILD). Using an independent cohort, we show that the group with more severe ILD was more likely to show forced vital capacity decline over a period of 36–54 months. Our results demonstrate an association among the activation of regulators, gene expression subsets, and clinical variables that can identify patients with SSc with more severe disease. |
format | Online Article Text |
id | pubmed-7526449 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | American Society for Clinical Investigation |
record_format | MEDLINE/PubMed |
spelling | pubmed-75264492020-10-05 Regulator combinations identify systemic sclerosis patients with more severe disease Wang, Yue Franks, Jennifer M. Yang, Monica Toledo, Diana M. Wood, Tammara A. Hinchcliff, Monique Whitfield, Michael L. JCI Insight Research Article Systemic sclerosis (SSc) is a heterogeneous autoimmune disorder that results in skin fibrosis, autoantibody production, and internal organ dysfunction. We previously identified 4 “intrinsic” subsets of SSc based upon skin gene expression that are found across organ systems. Gene expression regulators that underlie the SSc-intrinsic subsets, or are associated with clinical covariates, have not been systematically characterized. Here, we present a computational framework to calculate the activity scores of gene expression regulators and identify their associations with SSc clinical outcomes. We found that regulator activity scores can reproduce the intrinsic molecular subsets, with distinct sets of regulators identified for inflammatory, fibroproliferative, limited, and normal-like samples. Regulators most highly correlated with modified Rodnan skin score (MRSS) also varied by intrinsic subset. We identified subgroups of patients with fibroproliferative and inflammatory SSc with more severe pathophenotypes, such as higher MRSS and increased likelihood of interstitial lung disease (ILD). Using an independent cohort, we show that the group with more severe ILD was more likely to show forced vital capacity decline over a period of 36–54 months. Our results demonstrate an association among the activation of regulators, gene expression subsets, and clinical variables that can identify patients with SSc with more severe disease. American Society for Clinical Investigation 2020-09-03 /pmc/articles/PMC7526449/ /pubmed/32721949 http://dx.doi.org/10.1172/jci.insight.137567 Text en © 2020 Wang et al. http://creativecommons.org/licenses/by/4.0/ This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Research Article Wang, Yue Franks, Jennifer M. Yang, Monica Toledo, Diana M. Wood, Tammara A. Hinchcliff, Monique Whitfield, Michael L. Regulator combinations identify systemic sclerosis patients with more severe disease |
title | Regulator combinations identify systemic sclerosis patients with more severe disease |
title_full | Regulator combinations identify systemic sclerosis patients with more severe disease |
title_fullStr | Regulator combinations identify systemic sclerosis patients with more severe disease |
title_full_unstemmed | Regulator combinations identify systemic sclerosis patients with more severe disease |
title_short | Regulator combinations identify systemic sclerosis patients with more severe disease |
title_sort | regulator combinations identify systemic sclerosis patients with more severe disease |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7526449/ https://www.ncbi.nlm.nih.gov/pubmed/32721949 http://dx.doi.org/10.1172/jci.insight.137567 |
work_keys_str_mv | AT wangyue regulatorcombinationsidentifysystemicsclerosispatientswithmoreseveredisease AT franksjenniferm regulatorcombinationsidentifysystemicsclerosispatientswithmoreseveredisease AT yangmonica regulatorcombinationsidentifysystemicsclerosispatientswithmoreseveredisease AT toledodianam regulatorcombinationsidentifysystemicsclerosispatientswithmoreseveredisease AT woodtammaraa regulatorcombinationsidentifysystemicsclerosispatientswithmoreseveredisease AT hinchcliffmonique regulatorcombinationsidentifysystemicsclerosispatientswithmoreseveredisease AT whitfieldmichaell regulatorcombinationsidentifysystemicsclerosispatientswithmoreseveredisease |